Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
Dermatol Ther. 2020 May 30;:
Authors: Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadeh-Bazargan A, Hanifiha M, Goodarzi A
The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences and Google Scholar up to March 20, 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, anti-fibrosis, oxygenation, circulation, bronchodilator, ARDS and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline n controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for covid-19 treatment, especially as an adjuvant therapy in combination with other drugs. This article is protected by copyright. All rights reserved.
PMID: 32473070 [PubMed - as supplied by publisher]